Web17 sep. 2024 · This page shows recent SEC filings related to Melinta Therapeutics, Inc. Latest Categorized Press & Misc Exhibits Correspondence Press Releases (Most … WebMelinta Therapeutics, LLC - Unparalleled in passion & purpose. Medical Information For medical inquiries or to report an adverse event, other safety-related information, or …
MLNT SEC Filings - Melinta Therapeutics, Inc. - Annual Report, …
Web12 mei 2016 · New Haven, CT (GLOBE NEWSWIRE) - Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results from the second Phase 3 study (RX-3341-303 NCT01984684) of Baxdela (delafloxacin), an investigational anionic quinolone in development for the … Web20 feb. 2024 · NEW HAVEN, Conn., Feb. 20, 2024 -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections ... inter. pharmacy panama corp
Melinta Therapeutics - MLNT Stock Forecast, Price & News
Web24 jun. 2024 · On June 19 th, 2024 Melinta Therapeutics ( MLNT) announced the FDA accepted its BAXDELA sNDA for priority review. This sNDA would expand BAXDELA's … WebMelinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to introducing new antibiotics that meet the ever-present challenge posed by dangerous … Web9 aug. 2024 · In June, Melinta’s Baxdela received FDA approval for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). new england chowderheads